Friday, 16 October 2026European Markets

VALNEVA Stock Bullish By 15% So Far Today

Loading stream...

(vianews) - shares of valneva (cac 40: vla.pa) jumped by a staggering 15.28% to €4.85 at 11:05 est on thursday, following the last session's downward trend. cac 40 is dropping 0.27% to €7,383.51, following the last session's upward trend. this seems, at the moment, a somewhat bearish trend trading session today.

about valneva

valneva se, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. it offers ixiaro, an inactivated vero cell culture-derived japanese encephalitis vaccine indicated for active immunization against japanese encephalitis; dukoral, an oral vaccine for the prevention of diarrhea caused by vibrio cholera and/or heat-labile toxin producing enterotoxigenic escherichia coli bacterium; and vla2001, an inactivated whole-virus covid-19 vaccine. the company also develops vla15, a vaccine candidate, which is in phase iii clinical trial against borrelia, the bacterium that causes lyme disease; vla1553, a vaccine candidate, which is in phase iii clinical trial against the chikungunya virus; vla1554, a vaccine candidate targeting human metapneumovirus; and vla2112, a vaccine candidate to treat patients with epstein-barr virus. it sells its products in the united states, canada, germany, austria, nordics, the united kingdom, france, rest of european countries, and internationally. valneva se has collaborations with pfizer, inc. to co-develop and commercialize its lyme disease vaccine; and instituto butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. the company was founded in 1998 and is based in saint-herblain, france.

earnings per share

as for profitability, valneva has a trailing twelve months eps of €-1.16.

volume

today's last reported volume for valneva is 658498 which is 86.77% above its average volume of 352559.

volatility

valneva's last week, last month's, and last quarter's current intraday variation average was a negative 0.85%, a negative 0.88%, and a positive 1.91%.

valneva's highest amplitude of average volatility was 1.54% (last week), 1.95% (last month), and 1.91% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, valneva's stock is considered to be overbought (>=80).

more news about valneva (vla.pa).

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com